In the present study, we found that high expression of TRPM7 trended to be associated with poor survival only in the Lumina A breast cancer patients by analyzing TCGA database (Fig. 2).This was also supported by our data showing a negative relationship betweenTRPM7methylation with survival times after surgery (median survival time: 133.3 vs 125.1 months; P = 0.05) in our cohort (Fig. 3). This evidence concerns the gene TRPM7 and breast carcinoma.